By Samir A. Shah, Ph.D., Devices and Digital Therapeutics, CMC Regulatory Affairs, AstraZeneca
Software-enabled combination products demand early cross-functional alignment, regulatory foresight, and collaboration to avoid delays and accelerate patient access.